CClinicalTrials.gg
CompletedNCT03406520Updated Mar 23, 2020

Chlorhexidine Disk for Prevention of Exit-site Infection in Peritoneal Dialysis Patients

An interventional study of Chlorhexidine-impregnated disk in Peritoneal Dialysis Catheter Exit Site Infection, sponsored by Singapore General Hospital. Completed at 1 site in Singapore. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-03-23.

Sponsored by Singapore General Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
21 Years to 90 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the efficacy and safety of chlorhexidine-impregnated disk in preventing catheter exit-site infection in peritoneal dialysis patients

Read the detailed description

The primary aim of the study is to examine the exit-site infection rate in patients using chlorhexidine-impregnated dressing.

The participant will be followed up at 2, 6, 12, 24, 36 and 52 weeks of study and during each visit the catheter exit-site will be examined by one of the investigators for any sign of infection or allergic reaction, and questionnaires about satisfaction with use of study material (biopatch) will be asked by a study team member at the 12 week visit of the study. Each participant will be followed up for one year.

02

Conditions studied

  • Peritoneal Dialysis Catheter Exit Site Infection

Keywords

  • peritoneal dialysis
  • chlorhexidine
  • exit site infection
  • tunnel tract infection
03

Who can participate

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All adult incident peritoneal dialysis patients between 21 to 90 years old, who are followed up in Singapore General Hospital

Exclusion criteria

Exclusion Criteria:

  1. patients who have known history of allergy to chlorhexidine
  2. patients who had previous history of peritoneal dialysis catheter exit-site infection
  3. patients with mentally challenging conditions who are unable to give the valid consent for the study
  4. patients who have been involved in another study for exit site infection
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Chlorhexidine-impregnated disk

    The chlorhexidine-impregnated disk, will be applied to the peritoneal dialysis catheter exit-site and the disk will be changed once a week

    Device: Chlorhexidine-impregnated disk

Interventions

  • DeviceChlorhexidine-impregnated disk

    The chlorhexidine-impregnated sponge, named biopatch, is a protective disk (2.5 cm x 0.7 cm), which is hydrophilic polyurethane absorptive foam with chlorhexidine gluconate, in average of 86.8mg per disk

    Also known as: biopatch disk

05

What researchers measure

Primary outcomes

  1. Exit-site/tunnel infection rate

    Exit-site/tunnel infection rate (reported as episodes per patient-year) in patients receiving chlorhexidine-impregnated disk

    Time frame: one year

Secondary outcomes

  1. Time to the first episode of exit-site/tunnel infection

    days from peritoneal dialysis initiation to the time develops first exit-site/tunnel infection

    Time frame: one year

  2. peritonitis rate

    Peritonitis rate (reported as episodes per patient-year) in patients receiving chlorhexidine-impregnated disk

    Time frame: one year

  3. time to first episode of peritonitis

    days from peritoneal dialysis initiation to the time develops first episode of peritonitis

    Time frame: one year

  4. Peritoneal dialysis infection-related hospitalization

    Hospitalization due to peritoneal dialysis-related infection

    Time frame: one year

  5. technique failure rate

    technique failure is defined as transfer to hemodialysis for \>= 30 days

    Time frame: one year

  6. adverse events

    any local or systemic adverse events

    Time frame: one year

  7. mortality

    all-cause mortality

    Time frame: one year

  8. patient satisfaction with the use of chlorhexidine-impregnated sponge dressing

    Questionnaires related to the treatment with chlorhexidine-impregnated disk

    Time frame: third month of study

  9. comparison of the above outcomes with historical cohort using topical antibiotics cream

    comparison of exit-site/tunnel infection rate, peritonitis rate, time to first episode of exit-site/tunnel infection or peritonitis, technique failure rate, hospitalization rate, adverse events, mortality with historical cohort patients using topical gentamicin cream

    Time frame: one year

06

Study locations

1 site
  • Singapore General Hospital
    Singapore, 169856, Singapore
07

References and documents

Publications

  • Htay H, Choo JCJ, Johnson DW, Pascoe EM, Jayaballa M, Oei EL, Ng LC, Wu SY, Foo MWY. Chlorhexidine-impregnated sponge dressing for prevention of catheter exit-site infection in peritoneal dialysis patients: a pilot study. Int Urol Nephrol. 2021 Apr;53(4):803-812. doi: 10.1007/s11255-020-02674-w. Epub 2020 Oct 6. PubMed 33025409 ↗

Study documents

  • Protocol and statistical analysis plan · Oct 4, 2017

Documents are hosted by the registry — open the source record to download them.

08

Registry details

Key details

Study ID
NCT03406520
Lead sponsor
Singapore General Hospital
Collaborators
Johnson & Johnson
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Mar 7, 2018
Primary completion
Oct 1, 2019
Completion
Oct 25, 2019
Last update
Mar 23, 2020

Study contacts

Htay Htay
principal investigator · Singapore General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion